Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

Congratulations Circadian

Yesterday’s announcement that Opthea (née Circadian, ASX : CIR) completely restructured its board, is good news for the company – but it is also good news for the biotech industry. Opthea’s board reshuffle, in my opinion, follows on what has been a spate of shareholder backlash to underperforming bioscience companies, and it is great to…

Optheapology

In a prior post I lightly dissed Circadian’s new name (ASX : CIR) – Opthea. In my defence, you surely knew it was coming… though I should clarify, for the avoidance of doubt, that I have always liked the name Opthea better than “sister company” Vegenics. Yuk. The word “vegenics” can only ever be credibly used in the following sentence…

Is Clinuvel Relevant?

I will state from the outset, I don’t like this company, but not for reasons that will dissuade most people from taking a look at the stock. It’s funny because I get a lot of flack for writing posts about baby ASX biopharma companies that I actually do sort of like. I do sort of…

Welcome, Opthea

It was with great joy and happiness today, that I read Circadian’s (ASX : CIR) AGM agenda. This is a big deal. Finally, the company has decided to change its name and re-identify itself as the inner person it always needed to be : Opthea. It’s not a perfect brand, mind-you. When I think of Opthea,…

A Cancer-Free Circadian

Today’s announcement that Circadian (ASX : CIR) has “regained” the VEGFR-3 IP from Lilly is obviously a bit of word-smithing for the reality that Lilly has elected not to proceed with the program. Ok, I will let the spin go this time, mainly because I sort of believe it’s true. Circadian’s biggest enemy is itself and its…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…